GCP
CRDF icon

GSA Capital Partners’s Cardiff Oncology CRDF Stock Holding History

GSA Capital Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
173,274
+50,266
+41% +$79.8K 0.01% 1473
2026
Q1 		$199K Sell
123,008
-87,872
-42% -$180K 0.01% 1458
2025
Q4 		$593K Buy
+210,880
New +$490K 0.05% 700
2025
Q3 		– Sell
-129,731
Closed -$409K – 1718
2025
Q2 		$409K Sell
129,731
-224,826
-63% -$686K 0.03% 1051
2025
Q1 		$1.11M Sell
354,557
-25,513
-7% -$101K 0.1% 296
2024
Q4 		$1.65M Buy
380,070
+193,420
+104% +$605K 0.12% 146
2024
Q3 		$498K Buy
186,650
+151,613
+433% +$358K 0.04% 908
2024
Q2 		$78K Buy
+35,037
New +$132K 0.01% 1546
2023
Q4 		– Sell
-25,975
Closed -$36K – 1553
2023
Q3 		$36K Sell
25,975
-270,702
-91% -$457K ﹤0.01% 1429
2023
Q2 		$436K Buy
296,677
+15,998
+6% +$25.8K 0.04% 826
2023
Q1 		$463K Sell
280,679
-71,507
-20% -$123K 0.05% 767
2022
Q4 		$493K Buy
352,186
+234,312
+199% +$336K 0.06% 609
2022
Q3 		$182K Buy
117,874
+579
+0.5% +$1.39K 0.02% 1256
2022
Q2 		$258K Buy
117,295
+53,546
+84% +$89.7K 0.04% 918
2022
Q1 		$158K Buy
63,749
+48,237
+311% +$171K 0.02% 1224
2021
Q4 		$93K Buy
+15,512
New +$92.5K 0.01% 1316
2021
Q3 		– Sell
-24,214
Closed -$161K – 1489
2021
Q2 		$161K Buy
+24,214
New +$205K 0.02% 1212
2017
Q2 		– Sell
-236
Closed -$20K – 1713
2017
Q1 		$20K Buy
+236
New +$32K ﹤0.01% 1701
2016
Q3 		– Sell
-153
Closed -$50K – 1792
2016
Q2 		$50K Buy
+153
New +$52.7K ﹤0.01% 1696

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's CRDF Position: Q2 2026 in Review

GSA Capital Partners increased its Cardiff Oncology (CRDF) stake by 41% in Q2 2026, buying an estimated $79.8K and bringing the position to 173,274 shares worth $225K. The position accounts for 0.01% of the portfolio, ranked #1473.

GSA Capital Partners first reported a position in CRDF in Q2 2016 and has held it in 19 quarters since. The position peaked at $1.65M in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • GSA Capital Partners held 173,274 shares of Cardiff Oncology worth $225K as of Q2 2026.
  • GSA Capital Partners bought 50,266 Cardiff Oncology shares in Q2 2026, an estimated $79.8K.
  • Cardiff Oncology made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1473 holding.
  • GSA Capital Partners first reported a position in Cardiff Oncology in Q2 2016 and has held it in 19 quarters since.
  • GSA Capital Partners's Cardiff Oncology position peaked at $1.65M in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.